Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System

Exclusion Criteria

• •Genetic Bleeding disorders. Known or subsequently discovered inherited defects of coagulation (e.g. hemophilia or Von Willebrand disease)
• •Not known when last two DOAC doses were administered prior to blood draw
• •DOAC first administered (or resumed after temporary cessation) less than 7 days prior to blood draw
• •DOAC dosage outside of manufacturer's recommended range (e.g. study subject with renal impairment and supratherapeutic dose)
• •Heparin or LMWH administered within 7 days prior to blood draw
• •On any medications known to affect coagulation status and listed below
• •Bruising, wounds or scarring in the area of venipuncture
• •List of medications known to affect coagulation status
• •1. Vitamin K Antagonists \[VKAs\] Warfarin Phenprocoumon Acenocoumarol Tecarfarin \[ATI-5923\] Phenindione Anisindione Elinogrel Vorapaxar Atopaxar
• •2. Heparin and Heparins Unfractionated Heparin \[UFH\] LMWH Fondaparinux Idraparinux Danaparoid
• •3. Vasopressin Analogues DDAVP
• •4. Direct Thrombin \[IIa\] Inhibitors Hirudin Lepirudin Bivalirudin Argatroban
• •5. Defibrinating Agents Ancrod